TGFB1 and idiopathic pulmonary fibrosis: As aforementioned, to overcome the variability between IPF fibroblasts, a pre-treatment with recombinant TGF-β is required to activate the IPF fibroblasts and enhance the expression of the profibrotic markers ACTA2, COL1A1, and Fibronectin.